MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment

被引：36

作者：

Grabek, Julian ^{[1
,2
]}

Straube, Jasmin ^{[1
,2
]}

Bywater, Megan ^{[1
,2
]}

Lane, Steven W. ^{[1
,2
,3
]}

机构：

[1] QIMR Berghofer Med Res Inst, Canc Program, Brisbane, Qld 4006, Australia

[2] Univ Queensland, Fac Med, Brisbane, Qld 4072, Australia

[3] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld 4029, Australia

来源：

CELLS | 2020年 / 9卷 / 08期

关键词：

MPN; myeloproliferation; JAK2; CALR; MPL; driver mutations; leukemic transformation; IFN alpha; chromatin modifiers; spliceosome; DNA methylation; tumour suppressors; transcriptional regulators; HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; MYELOPROLIFERATIVE NEOPLASMS; AVAILABLE THERAPY; THROMBOPOIETIN RECEPTOR; LEUKEMIC TRANSFORMATION; PRIMARY MYELOFIBROSIS; MOUSE MODEL;

D O I：

10.3390/cells9081901

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Myeloproliferative neoplasms (MPNs) constitute a group of disorders identified by an overproduction of cells derived from myeloid lineage. The majority of MPNs have an identifiable driver mutation responsible for cytokine-independent proliferative signalling. The acquisition of coexisting mutations in chromatin modifiers, spliceosome complex components, DNA methylation modifiers, tumour suppressors and transcriptional regulators have been identified as major pathways for disease progression and leukemic transformation. They also confer different sensitivities to therapeutic options. This review will explore the molecular basis of MPN pathogenesis and specifically examine the impact of coexisting mutations on disease biology and therapeutic options.

引用

页数：32

共 213 条

[71] Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells [J].

Guenther, Kacey L. ;

Cheruku, Patali S. ;

Cash, Ayla ;

Smith, Richard H. ;

Alvarado, Luigi J. ;

Burkett, Sandra ;

Townsley, Danielle M. ;

Winkler, Thomas ;

Larochelle, Andre .

EXPERIMENTAL HEMATOLOGY, 2019, 73 :1-6

[72] Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) [J].

Guglielmelli, Paola ;

Bartalucci, Niccolo ;

Contini, Elisa ;

Rotunno, Giada ;

Pacilli, Annalisa ;

Romagnoli, Simone ;

Mannelli, Lara ;

Mannelli, Francesco ;

Coltro, Giacomo ;

Pancrazzi, Alessandro ;

Ariu, Valentina ;

Fiaccabrino, Sara ;

Semeraro, Roberto ;

Magi, Alberto ;

Mannarelli, Carmela ;

Gesullo, Francesca ;

Paoli, Chiara ;

Vannucchi, Alessandro M. .

BLOOD, 2019, 134

[73] Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis [J].

Guglielmelli, Paola ;

Rotunno, Giada ;

Bogani, Costanza ;

Mannarelli, Carmela ;

Giunti, Laura ;

Provenzano, Aldesia ;

Giglio, Sabrina ;

Squires, Matthew ;

Stalbovskaya, Viktoriya ;

Gopalakrishna, Prashanth ;

Vannucchi, Alessandro M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (06) :938-940

[74] EZH2 mutational status predicts poor survival in myelofibrosis [J].

Guglielmelli, Paola ;

Biamonte, Flavia ;

Score, Joannah ;

Hidalgo-Curtis, Claire ;

Cervantes, Francisco ;

Maffioli, Margherita ;

Fanelli, Tiziana ;

Ernst, Thomas ;

Winkelman, Nils ;

Jones, Amy V. ;

Zoi, Katerina ;

Reiter, Andreas ;

Duncombe, Andrew ;

Villani, Laura ;

Bosi, Alberto ;

Barosi, Giovanni ;

Cross, Nicholas C. P. ;

Vannucchi, Alessandro M. .

BLOOD, 2011, 118 (19) :5227-5234

[75] The multiple mechanisms that regulate p53 activity and cell fate [J].

Hafner, Antonina ;

Bulyk, Martha L. ;

Jambhekar, Ashwini ;

Lahav, Galit .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (04) :199-210

[76] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[77] Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure [J].

Harrison, Claire N. ;

Schaap, Nicolaas ;

Vannucchi, Alessandro M. ;

Kiladjian, Jean-Jacques ;

Jourdan, Eric ;

Silver, Richard T. ;

Schouten, Harry C. ;

Passamonti, Francesco ;

Zweegman, Sonja ;

Talpaz, Moshe ;

Verstovsek, Srdan ;

Rose, Shelonitda ;

Shen, Juan ;

Berry, Tymara ;

Brownstein, Carrie ;

Mesa, Ruben A. .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) :594-603

[78] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial [J].

Harrison, Claire N. ;

Vannucchi, Alessandro M. ;

Platzbecker, Uwe ;

Cervantes, Francisco ;

Gupta, Vikas ;

Lavie, David ;

Passamonti, Francesco ;

Winton, Elliott F. ;

Dong, Hua ;

Kawashima, Jun ;

Maltzman, Julia D. ;

Kiladjian, Jean-Jacques ;

Verstovsek, Srdan .

LANCET HAEMATOLOGY, 2018, 5 (02) :E73-E81

[79] Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide [J].

Harrison, Claire N. ;

Mead, Adam J. ;

Panchal, Anesh ;

Fox, Sonia ;

Yap, Christina ;

Gbandi, Emmanouela ;

Houlton, Aimee ;

Alimam, Samah ;

Ewing, Joanne ;

Wood, Marion ;

Chen, Frederick ;

Coppell, Jason ;

Panoskaltsis, Nicki ;

Knapper, Steven ;

Ali, Sahra ;

Hamblin, Angela ;

Scherber, Robyn ;

Dueck, Amylou C. ;

Cross, Nicholas C. P. ;

Mesa, Ruben ;

McMullin, Mary Frances .

BLOOD, 2017, 130 (17) :1889-1897

[80] Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study [J].

Harrison, Claire N. ;

Schaap, Nicolaas ;

Vannucchi, Alessandro M. ;

Kiladjian, Jean-Jacques ;

Tiu, Ramon V. ;

Zachee, Pierre ;

Jourdan, Eric ;

Winton, Elliott ;

Silver, Richard T. ;

Schouten, Harry C. ;

Passamonti, Francesco ;

Zweegman, Sonja ;

Talpaz, Moshe ;

Lager, Joanne ;

Shun, Zhenming ;

Mesa, Ruben A. .

LANCET HAEMATOLOGY, 2017, 4 (07) :E317-E324

← 3 4 5 6 7 8 9 10 11 12 →